Gilead Sciences Reports $7.77 Billion Revenue in Q3 2025, Net Income Rises to $3.05 Billion

Gilead Sciences, Inc. reported a total revenue of $7.77 billion for the third quarter of 2025, marking a 3% increase from $7.55 billion in the same period last year. The growth was primarily driven by higher royalty, contract, and other revenues, alongside increased sales in HIV and liver disease products. For the nine months ending September 30, 2025, total revenues reached $21.52 billion, a 2% rise from $21.19 billion in the prior year. The company also reported a net income of $3.05 billion for the quarter, a significant increase from $1.25 billion in Q3 2024, and a net income of $6.33 billion for the nine-month period, compared to a net loss of $1.30 billion in the same timeframe last year.

The financial performance reflects a notable recovery from previous fiscal challenges, particularly due to the absence of substantial impairment charges that affected results in 2024. Gilead's earnings per share (EPS) for the third quarter were $2.43, up from $1.00 a year earlier, while the nine-month EPS was $5.04, compared to a loss of $1.04 in 2024. The improved profitability was attributed to lower in-process research and development (IPR&D) expenses and higher revenues from key product lines, including Biktarvy and Descovy, which saw increased demand.

Strategically, Gilead has made significant moves, including the acquisition of Interius BioTherapeutics for approximately $350 million, aimed at enhancing its oncology portfolio. The company also received FDA approval for Yeztugo, a twice-yearly injectable for HIV pre-exposure prophylaxis, and secured a partnership with the U.S. State Department to deliver this treatment to millions in need. Additionally, Gilead has settled patent litigation regarding Biktarvy, extending its market exclusivity until at least 2036.

Operationally, Gilead's product sales for HIV reached $5.28 billion in Q3 2025, a 4% increase from the previous year, while liver disease product sales rose 12% to $819 million. However, sales of Veklury, its COVID-19 treatment, plummeted by 60% due to decreased hospitalization rates. The company reported a total employee headcount of approximately 14,000, reflecting ongoing adjustments in workforce management.

Looking ahead, Gilead anticipates continued growth driven by its expanding product portfolio and strategic partnerships. The company remains focused on addressing unmet medical needs in various therapeutic areas, including HIV, oncology, and liver diseases, while managing operational costs and enhancing shareholder value through dividends and share repurchases.